Muscle wasting is a common consequence of critical illness, and has a profound impact upon the rehabilitation of those who survive admission to critical to care. The investigators intend to assess if the application of 10 sessions over two weeks of passive cycling with electrical stimulation to the lower limbs and abdomen can prevent muscle loss, or at least cause less muscle loss, compared to patients who receive standard daily sessions of physiotherapy. This will be done by comparing the changes in muscle size on ultrasound between the two groups, comparing functional measures at a 3 month follow up, and by performing translational research using tissue samples taken during the study.
Patients are mechanically ventilated and sedated with a diagnosis of sepsis (from any source) will be eligible for this study. Provided they meet the inclusion criteria, they will be randomised within 48 hours of admission, to either ten 30 minute sessions of passive cycling with functional electrical stimulation (FES) to the thighs, hamstrings, calves and abdomen over a 14 day period, or to a control group of routine physiotherapy. The trial group will also receive this physiotherapy. On admission to the study, all patients will receive on day 1: Ultrasound measurements of: Rectus femoris cross-sectional area Thickness of rectus femoris and vastus intermedius Thickness, pennation angle and derived fascicle length of vastus lateralis and medial head of gastrocnemius Thickness of rectus abdominis. Thickness of diaphragm A blood sample taken from an arterial line A urine sample taken from a urinary catheter A muscle biopsy taken from the right vastus lateralis They will then receive ten 30 minute sessions of passive cycling with functional electrical stimulation over 14 days, or a control group will receive routine physiotherapy during this period. Repeat ultrasounds will be taken at days 3, 5, 7, 10 and 14. Repeat blood and urine sampling at days 5, 10 and 14. Repeat muscle biopsy at day 14. All cycling, ultrasounds and tissue sampling will end on day 14 regardless of the ventilator status of the patient. In patients who survive to be discharged from critical care, they will be followed up at 3 months for: Repeat ultrasound scan of all muscles listed Six minute walk test Hand grip and lower limb dynamometry, Balance testing (by standing upright on a pressure plate for 20 seconds) Psychological assessment using the 36 item Short Form (SF-36) questionnaire Tissue sampling will be stored in the University of Liverpool for analysis of biomarkers of muscle damage and loss between the two groups.
Study Type
INTERVENTIONAL
As described already
As described already
Intensive Care Unit, Royal Liverpool University Hospital
Liverpool, United Kingdom
Ultrasound assessment of rectus femoris - Change in cross sectional area (cm2)
Measurement of cross-sectional area of rectus femoris (cm2)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of rectus femoris - Change in muscle layer thickness (cm)
Measurement on muscle layer thickness of rectus femoris (cm)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of anterior thigh musculature - Change in muscle layer thickness (cm)
Measurement of combined muscle layer thickness of rectus femoris and vastus intermedius (cm)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of vastus lateralis - change in muscle layer thickness (cm)
Measurement of the thickness of the vastus lateralis between the superficial and deep aponeuroses (cm)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of vastus lateralis - change in fascicle pennation angle (degrees)
Measurement of the pennation angle of the muscle fascicles as they insert into the deep aponeuroses of the vastus lateralis muscle (degrees)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of vastus lateralis - change in fascicle length (cm)
This is a single measure, derived by trigonometry (the Sine of the pennation angle multiplied by the muscle thickness).
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
32
Ultrasound assessment of the medial head of gastrocnemius - change in muscle thickness (cm)
Measurement of the thickness of the medial head of the gastrocnemius between the superficial and deep aponeuroses (cm)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of the medial head of gastrocnemius - change in fascicle pennation angle (degrees)
Measurement of the pennation angle of the muscle fascicles as they insert into the deep aponeuroses of the medial head of gastrocnemius (angles)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of the medial head of gastrocnemius - change in fascicle length (cm)
This is single measure which is mathematically derived by trigonometry using the known pennation angle (degrees) and thickness (cm): the Sine of the pennation angle multiplied by the muscle thickness.
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of the rectus abdominis muscle - change in muscle layer thickness (cm)
Measurement of rectus abdominis muscle layer thickness - (cm)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Diaphragm thickness assessment by ultrasound - change in end expiratory thickness (mm)
Assessment of thickness at end expiration (mm)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Diaphragm thickness assessment by ultrasound - change in end inspiratory thickness (mm)
Assessment of thickness at end inspiration (mm)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Diaphragm thickness assessment by ultrasound - change in thickening fraction (%)
Assessment of thickening fraction, derived mathematically from thicknesses at inspiration and expiration (%)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Ultrasound assessment of change in diaphragmatic excursion (cm)
Assessment of maximal excursion of diaphragm, measured with M-mode ultrasonography (mm)
Time frame: Ultrasounds taken on day 1, 3, 5, 7, 10 and 14, and at 3 month follow up.
Measurement of change in blood biomarkers (microRNA analysis for markers of muscle loss, expressed as a percentage fold increase/decrease compared to baseline).
Blood samples taken during the study period and analysed for markers of muscle loss/degradation
Time frame: Samples taken on days 1, 5, 10 and 14
Measurement of change in urinary biomarkers (microRNA analysis for markers of muscle loss, expressed as a percentage-fold increase/decrease compared to baseline).
Blood and urine samples taken during the study period and analysed for markers of muscle loss/degradation
Time frame: Samples taken on days 1, 5, 10 and 14
Measurement of the number of biomarkers expressed from muscle biopsies (microRNA analysis for markers of muscle loss, expressed as the number and type of micro-RNAs expressed within the samples).
Muscle biopsy samples taken during the study period and analysed for markers of muscle loss/degradation. Number and type of micro-RNAs to be noted).
Time frame: Samples taken on day 1 and 14
Measurement of muscle fibre cross sectional area from muscle biopsies (mm2)
Histological staining and analysis of muscle fibre composition, expressed in square millimetres and as a percentage-fold increase/decrease compared to baseline).
Time frame: Samples taken on day 1 and 14
Follow up testing - Distance achieved in a 6 minute walk test, metres)
Distance achieved during a 6 minute shuttle walk of 20 metres length
Time frame: At 3 month follow up
Follow up testing - Hand grip dynamometry (hand grip strength, Newtons)
Strength of hand grip in both hands
Time frame: At 3 month follow up
Follow up - Lower limb strength assessment - Force generated at maximal contraction for knee extension (Newtons)
Strength of extension at the knee in both legs using a hand held dynamometry device (microFET 2 wireless device). Measured in Newtons.
Time frame: At 3 month follow up
Follow up testing - Balance assessment - Comparison of changes in center of pressure on a pressure plate.
Comparison of changes in centre of pressure on a pressure plate. The centre of pressure is measured over 20 seconds with the participant standing still. Maximal variation in lateral and anterior-posterior sway is recorded by the pressure plate.
Time frame: At 3 month follow up
Follow up testing - Psychological assessment - Comparison of total scores obtained from the SF-36 questionnaire (maximum score 100, minimum score zero).
Comparison of scores obtained from the SF-36 questionnaire between the two groups. A lower score indicates greater disability.
Time frame: At 3 month follow up
Follow Up - Maximal Inspiratory Pressure monitoring in kilopascals (kPa)
Using the Power Breathe K2 device
Time frame: At 3 month follow up
Incidence of delirium during the trial period - using the CAM-ICU tool.
Assessed by twice daily Cambridge Assessment Method for the ICU (CAM-ICU) assessments
Time frame: Days 1-14
Incidence of renal replacement therapy during the trial period
Daily monitoring to see if patient has required renal replacement therapy (defined as either haemofiltration or haemodialysis).
Time frame: Days 1-14
Total dose of noradrenaline given per day
Daily monitoring of doses of inotropic and vasopressor drugs
Time frame: Day 1-14
Overall fluid balance (in mls) at the end of each study day
Daily noting of 24 hour fluid balance
Time frame: Day 1-14
Total Insulin doses (in international units) required per day
Daily monitoring of exogenous insulin requirements
Time frame: Day 1-14
Blood glucose concentration (mmol/L)
Daily monitoring of glucose levels
Time frame: Day 1-14
Heart rate variability
Measured via a wireless skin patch
Time frame: Days 1 - 14 but only on the days where cycling takes place (ten sessions)
Safety - number of times an endotracheal/tracheostomy tube is dislodged during the cycling sessions
Expressed as a simple count of how many times an airway device dislodges
Time frame: Days 1 - 14 but only on the days where cycling takes place (ten sessions)
Safety - number of times an nasogastric tube is dislodged during the cycling sessions
Expressed as a simple count of how many times a nasogastric feed tube dislodges.
Time frame: Days 1 - 14 but only on the days where cycling takes place (ten sessions).
Safety - number of times an a central or arterial line device is dislodged during the cycling sessions
Expressed as a simple count of how many times a central or arterial line dislodges.
Time frame: Days 1 - 14 but only on the days where cycling takes place (ten sessions).